BORELLI, BEATRICE Statistiche
BORELLI, BEATRICE
DIPARTIMENTO DI PATOLOGIA CHIRURGICA, MEDICA, MOLECOLARE E DELL'AREA CRITICA
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
2018-01-01 Masi, Gianluca; Borelli, Beatrice
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
2020-01-01 Miyamoto, Y.; Schirripa, M.; Suenaga, M.; Cao, S.; Zhang, W.; Okazaki, S.; Berger, M. D.; Matsusaka, S.; Yang, D.; Ning, Y.; Baba, H.; Loupakis, F.; Lonardi, S.; Pietrantonio, F.; Borelli, B.; Cremolini, C.; Yamaguchi, T.; Lenz, H. -J.
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
2020-01-01 Antoniotti, C.; Borelli, B.; Rossini, D.; Pietrantonio, F.; Morano, F.; Salvatore, L.; Lonardi, S.; Marmorino, F.; Tamberi, S.; Corallo, S.; Tortora, G.; Bergamo, F.; Brunella, D. S.; Boccaccino, A.; Grassi, E.; Racca, P.; Tamburini, E.; Aprile, G.; Moretto, R.; Boni, L.; Falcone, A.; Cremolini, C.
atypical RAS mutations in metastatic colorectal cancer
2019-01-01 Pietrantonio, F; Yaeger, R; Scrock, Ab; Randon, G; Romero-Cordoba, S; Rossini, D; Fucà, G; Ross, Js; Kotani, D; Madison, R; Kim, St; Salvatore, L; Raimondi, A; Pagani, F; Borelli, B; Perrone, F; Di, Bartolomeo; Miller, Va; Ali, Sm; Lee, J; Yoshino, T; de Braud, F; Falcone, A; Hechtman, Jf; Cremolini, C
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study
2019-01-01 Cremolini, Chiara; Benelli, Matteo; Fontana, Elisa; Pagani, Filippo; Rossini, Daniele; Fucà, Giovanni; Busico, Adele; Conca, Elena; Di Donato, Samantha; Loupakis, Fotios; Schirripa, Marta; Lonardi, Sara; Borelli, Beatrice; Ongaro, Elena; Eason, Katherine; Morano, Federica; Casagrande, Mariaelena; Fassan, Matteo; Sadanandam, Anguraj; De Braud, Filippo; Falcone, Alfredo; Pietrantonio, Filippo
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials
2022-01-01 Dell'Aquila, E; Rossini, D; Fulgenzi, C A M; Passardi, A; Tamburini, E; Vetere, G; Carullo, M; Citarella, F; Antoniotti, C; Zaniboni, A; Pietrantonio, F; Spagnoletti, A; Marmorino, F; Borelli, B; Allegrini, G; Lonardi, S; Nappo, F; Masi, G; Cremolini, C; Santini, D
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies
2021-01-01 Moretto, R.; Rossini, D.; Conca, V.; Lonardi, S.; Rasola, C.; Antoniotti, C.; Santini, D.; Marmorino, F.; Tomasello, G.; Borelli, B.; Caponnetto, S.; Zucchelli, G.; Zaniboni, A.; Ambrosini, M.; Buonadonna, A.; Fanchini, L.; Cupini, S.; Masi, G.; Falcone, A.; Cremolini, C.
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
2019-01-01 Ongaro, E.; Cremolini, C.; Rossini, D.; Corti, Filippo; Pagani, F.; Morelli, L.; Urbani, L.; Masi, G.; Sposito, C.; Filippi, B.; Borelli, B.; Zucchelli, G.; Moretto, R.; Boccaccino, A.; Solaini, L.; De Braud, F.; Mazzaferro, V.; Falcone, A.; Cucchetti, A.; Pietrantonio, F.
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients
2019-01-01 Catalano, V.; Bergamo, F.; Cremolini, C.; Vincenzi, B.; Negri, F.; Giordani, P.; Alessandroni, P.; Intini, R.; Stragliotto, S.; Rossini, D.; Borelli, B.; Santini, D.; Sarti, D.; Rocchi, M. B. L.; Lonardi, S.; Falcone, A.; Zagonel, V.; Mattioli, R.; Graziano, F.
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
2021-01-01 Rossini, D; Boccaccino, A; Sbrana, A; Daniel, F; Borelli, B; Raimondi, A; Santini, D; Conca, V; Tomasello, G; Caponnetto, S; Marmorino, F; Zaniboni, A; Buonadonna, A; Masi, G; Lonardi, S; Pietrantonio, F; Falcone, A; Antonuzzo, A; Cremolini, C
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
2017-01-01 Cremolini, Chiara; Del Re, Marzia; Antoniotti, Carlotta; Lonardi, Sara; Bergamo, Francesca; Loupakis, Fotios; Borelli, Beatrice; Marmorino, Federica; Citi, Valentina; Cortesi, Enrico; Moretto, Roberto; Ronzoni, Monica; Tomasello, Gianluca; Zaniboni, Alberto; Racca, Patrizia; Buonadonna, Angela; Allegrini, Giacomo; Ricci, Vincenzo; Donato, Samantha Di; Zagonel, Vittorina; Boni, Luca; Falcone, Alfredo; Danesi, Romano
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib
2019-01-01 Schirripa, Marta; Borelli, Beatrice; D'Aurizio, Romina; Lubrano, Simone; Cremolini, Chiara; Zucchelli, Gemma; Antoniotti, Carlotta; Marmorino, Federica; Prete, Alessandra Anna; Murgioni, Sabina; Bergamo, Francesca; Zagonel, Vittorina; Tuccoli, Andrea; Marranci, Andrea; Rizzo, Milena; Tedeschi, Lorena; Magnoni, Letizia; Falcone, Alfredo; Loupakis, Fotios; Poliseno, Laura
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer
2022-01-01 Antoniotti, C.; Marmorino, F.; Boccaccino, A.; Martini, S.; Antista, M.; Rossini, D.; Zuco, V.; Prisciandaro, M.; Conca, V.; Zucchelli, G.; Borelli, B.; Cosentino, P.; Germani, M. M.; Bosco, M. F.; Carullo, M.; Vetere, G.; Moretto, R.; Giordano, M.; Masi, G.; Pietrantonio, F.; Zaffaroni, N.; Cremolini, C.
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
2022-01-01 Boccaccino, A; Borelli, B; Intini, R; Antista, M; Bensi, M; Rossini, D; Passardi, A; Tamberi, S; Giampieri, R; Antonuzzo, L; Noto, L; Roviello, G; Zichi, C; Salati, M; Puccini, A; Noto, C; Parisi, A; Rihawi, K; Persano, M; Crespi, V; Libertini, M; Giordano, M; Moretto, R; Lonardi, S; Cremolini, C
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
2022-01-01 Antoniotti, C.; Germani, M. M.; Rossini, D.; Lonardi, S.; Pietrantonio, F.; Santini, D.; Marmorino, F.; Allegrini, G.; Daniel, F.; Raimondi, A.; Borelli, B.; Zaniboni, A.; Conca, V.; Abraham, J.; Spetzler, D.; Maiello, E.; Boccaccino, A.; Passardi, A.; Giordano, M.; Tamburini, E.; Korn, M. W.; Masi, G.; Cremolini, C.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
2020-01-01 Pietrantonio, Filippo; Fucà, Giovanni; Rossini, Daniele; Schmoll, Hans-Joachim; Bendell, Johanna C; Morano, Federica; Antoniotti, Carlotta; Corallo, Salvatore; Borelli, Beatrice; Raimondi, Alessandra; Marmorino, Federica; Niger, Monica; Boccaccino, Alessandra; Masi, Gianluca; Lonardi, Sara; Boni, Luca; de Braud, Filippo; Di Bartolomeo, Maria; Falcone, Alfredo; Cremolini, Chiara
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib
2018-01-01 Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Ning, Yan; Cremolini, Chiara; Antoniotti, Carlotta; Borelli, Beatrice; Mashima, Tetsuo; Okazaki, Satoshi; Berger, Martin D; Miyamoto, Yuji; Gopez, Roel; Barzi, Afsaneh; Lonardi, Sara; Yamaguchi, Toshiharu; Falcone, Alfredo; Loupakis, Fotios; Lenz, Heinz-Josef
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
2022-01-01 Borelli, Beatrice; Antoniotti, Carlotta; Carullo, Martina; Germani, Marco Maria; Conca, Veronica; Masi, Gianluca
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
2019-01-01 Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A; Latiano, T P; Cordio, S; Passardi, A; Tamburini, E; Boni, L; Falcone, A; Cremolini, C
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies
2019-01-01 Marmorino, F.; Rossini, D.; Lonardi, S.; Moretto, R.; Zucchelli, G.; Aprile, G.; Dell'Aquila, E.; Ratti, M.; Bergamo, F.; Masi, G.; Urbano, F.; Ronzoni, M.; Libertini, M.; Borelli, B.; Randon, G.; Buonadonna, A.; Allegrini, G.; Pella, N.; Ricci, V.; Boccaccino, A.; Latiano, T. P.; Cordio, S.; Passardi, A.; Tamburini, E.; Boni, L.; Falcone, A.; Cremolini, C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| [The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.] | 1-gen-2018 | Masi, Gianluca; Borelli, Beatrice | |
| A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer | 1-gen-2020 | Miyamoto, Y.; Schirripa, M.; Suenaga, M.; Cao, S.; Zhang, W.; Okazaki, S.; Berger, M. D.; Matsusaka, S.; Yang, D.; Ning, Y.; Baba, H.; Loupakis, F.; Lonardi, S.; Pietrantonio, F.; Borelli, B.; Cremolini, C.; Yamaguchi, T.; Lenz, H. -J. | |
| AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer | 1-gen-2020 | Antoniotti, C.; Borelli, B.; Rossini, D.; Pietrantonio, F.; Morano, F.; Salvatore, L.; Lonardi, S.; Marmorino, F.; Tamberi, S.; Corallo, S.; Tortora, G.; Bergamo, F.; Brunella, D. S.; Boccaccino, A.; Grassi, E.; Racca, P.; Tamburini, E.; Aprile, G.; Moretto, R.; Boni, L.; Falcone, A.; Cremolini, C. | |
| atypical RAS mutations in metastatic colorectal cancer | 1-gen-2019 | Pietrantonio, F; Yaeger, R; Scrock, Ab; Randon, G; Romero-Cordoba, S; Rossini, D; Fucà, G; Ross, Js; Kotani, D; Madison, R; Kim, St; Salvatore, L; Raimondi, A; Pagani, F; Borelli, B; Perrone, F; Di, Bartolomeo; Miller, Va; Ali, Sm; Lee, J; Yoshino, T; de Braud, F; Falcone, A; Hechtman, Jf; Cremolini, C | |
| Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study | 1-gen-2019 | Cremolini, Chiara; Benelli, Matteo; Fontana, Elisa; Pagani, Filippo; Rossini, Daniele; Fucà, Giovanni; Busico, Adele; Conca, Elena; Di Donato, Samantha; Loupakis, Fotios; Schirripa, Marta; Lonardi, Sara; Borelli, Beatrice; Ongaro, Elena; Eason, Katherine; Morano, Federica; Casagrande, Mariaelena; Fassan, Matteo; Sadanandam, Anguraj; De Braud, Filippo; Falcone, Alfredo; Pietrantonio, Filippo | |
| Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials | 1-gen-2022 | Dell'Aquila, E; Rossini, D; Fulgenzi, C A M; Passardi, A; Tamburini, E; Vetere, G; Carullo, M; Citarella, F; Antoniotti, C; Zaniboni, A; Pietrantonio, F; Spagnoletti, A; Marmorino, F; Borelli, B; Allegrini, G; Lonardi, S; Nappo, F; Masi, G; Cremolini, C; Santini, D | |
| CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | 1-gen-2021 | Moretto, R.; Rossini, D.; Conca, V.; Lonardi, S.; Rasola, C.; Antoniotti, C.; Santini, D.; Marmorino, F.; Tomasello, G.; Borelli, B.; Caponnetto, S.; Zucchelli, G.; Zaniboni, A.; Ambrosini, M.; Buonadonna, A.; Fanchini, L.; Cupini, S.; Masi, G.; Falcone, A.; Cremolini, C. | |
| Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable | 1-gen-2019 | Ongaro, E.; Cremolini, C.; Rossini, D.; Corti, Filippo; Pagani, F.; Morelli, L.; Urbani, L.; Masi, G.; Sposito, C.; Filippi, B.; Borelli, B.; Zucchelli, G.; Moretto, R.; Boccaccino, A.; Solaini, L.; De Braud, F.; Mazzaferro, V.; Falcone, A.; Cucchetti, A.; Pietrantonio, F. | |
| Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients | 1-gen-2019 | Catalano, V.; Bergamo, F.; Cremolini, C.; Vincenzi, B.; Negri, F.; Giordani, P.; Alessandroni, P.; Intini, R.; Stragliotto, S.; Rossini, D.; Borelli, B.; Santini, D.; Sarti, D.; Rocchi, M. B. L.; Lonardi, S.; Falcone, A.; Zagonel, V.; Mattioli, R.; Graziano, F. | |
| Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO | 1-gen-2021 | Rossini, D; Boccaccino, A; Sbrana, A; Daniel, F; Borelli, B; Raimondi, A; Santini, D; Conca, V; Tomasello, G; Caponnetto, S; Marmorino, F; Zaniboni, A; Buonadonna, A; Masi, G; Lonardi, S; Pietrantonio, F; Falcone, A; Antonuzzo, A; Cremolini, C | |
| DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer | 1-gen-2017 | Cremolini, Chiara; Del Re, Marzia; Antoniotti, Carlotta; Lonardi, Sara; Bergamo, Francesca; Loupakis, Fotios; Borelli, Beatrice; Marmorino, Federica; Citi, Valentina; Cortesi, Enrico; Moretto, Roberto; Ronzoni, Monica; Tomasello, Gianluca; Zaniboni, Alberto; Racca, Patrizia; Buonadonna, Angela; Allegrini, Giacomo; Ricci, Vincenzo; Donato, Samantha Di; Zagonel, Vittorina; Boni, Luca; Falcone, Alfredo; Danesi, Romano | |
| Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib | 1-gen-2019 | Schirripa, Marta; Borelli, Beatrice; D'Aurizio, Romina; Lubrano, Simone; Cremolini, Chiara; Zucchelli, Gemma; Antoniotti, Carlotta; Marmorino, Federica; Prete, Alessandra Anna; Murgioni, Sabina; Bergamo, Francesca; Zagonel, Vittorina; Tuccoli, Andrea; Marranci, Andrea; Rizzo, Milena; Tedeschi, Lorena; Magnoni, Letizia; Falcone, Alfredo; Loupakis, Fotios; Poliseno, Laura | |
| Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer | 1-gen-2022 | Antoniotti, C.; Marmorino, F.; Boccaccino, A.; Martini, S.; Antista, M.; Rossini, D.; Zuco, V.; Prisciandaro, M.; Conca, V.; Zucchelli, G.; Borelli, B.; Cosentino, P.; Germani, M. M.; Bosco, M. F.; Carullo, M.; Vetere, G.; Moretto, R.; Giordano, M.; Masi, G.; Pietrantonio, F.; Zaffaroni, N.; Cremolini, C. | |
| Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience | 1-gen-2022 | Boccaccino, A; Borelli, B; Intini, R; Antista, M; Bensi, M; Rossini, D; Passardi, A; Tamberi, S; Giampieri, R; Antonuzzo, L; Noto, L; Roviello, G; Zichi, C; Salati, M; Puccini, A; Noto, C; Parisi, A; Rihawi, K; Persano, M; Crespi, V; Libertini, M; Giordano, M; Moretto, R; Lonardi, S; Cremolini, C | |
| FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies | 1-gen-2022 | Antoniotti, C.; Germani, M. M.; Rossini, D.; Lonardi, S.; Pietrantonio, F.; Santini, D.; Marmorino, F.; Allegrini, G.; Daniel, F.; Raimondi, A.; Borelli, B.; Zaniboni, A.; Conca, V.; Abraham, J.; Spetzler, D.; Maiello, E.; Boccaccino, A.; Passardi, A.; Giordano, M.; Tamburini, E.; Korn, M. W.; Masi, G.; Cremolini, C. | |
| FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis | 1-gen-2020 | Pietrantonio, Filippo; Fucà, Giovanni; Rossini, Daniele; Schmoll, Hans-Joachim; Bendell, Johanna C; Morano, Federica; Antoniotti, Carlotta; Corallo, Salvatore; Borelli, Beatrice; Raimondi, Alessandra; Marmorino, Federica; Niger, Monica; Boccaccino, Alessandra; Masi, Gianluca; Lonardi, Sara; Boni, Luca; de Braud, Filippo; Di Bartolomeo, Maria; Falcone, Alfredo; Cremolini, Chiara | |
| Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib | 1-gen-2018 | Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Ning, Yan; Cremolini, Chiara; Antoniotti, Carlotta; Borelli, Beatrice; Mashima, Tetsuo; Okazaki, Satoshi; Berger, Martin D; Miyamoto, Yuji; Gopez, Roel; Barzi, Afsaneh; Lonardi, Sara; Yamaguchi, Toshiharu; Falcone, Alfredo; Loupakis, Fotios; Lenz, Heinz-Josef | |
| Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability | 1-gen-2022 | Borelli, Beatrice; Antoniotti, Carlotta; Carullo, Martina; Germani, Marco Maria; Conca, Veronica; Masi, Gianluca | |
| Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies | 1-gen-2019 | Marmorino, F; Rossini, D; Lonardi, S; Moretto, R; Zucchelli, G; Aprile, G; Dell'Aquila, E; Ratti, M; Bergamo, F; Masi, G; Urbano, F; Ronzoni, M; Libertini, M; Borelli, B; Randon, G; Buonadonna, A; Allegrini, G; Pella, N; Ricci, V; Boccaccino, A; Latiano, T P; Cordio, S; Passardi, A; Tamburini, E; Boni, L; Falcone, A; Cremolini, C | |
| Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies | 1-gen-2019 | Marmorino, F.; Rossini, D.; Lonardi, S.; Moretto, R.; Zucchelli, G.; Aprile, G.; Dell'Aquila, E.; Ratti, M.; Bergamo, F.; Masi, G.; Urbano, F.; Ronzoni, M.; Libertini, M.; Borelli, B.; Randon, G.; Buonadonna, A.; Allegrini, G.; Pella, N.; Ricci, V.; Boccaccino, A.; Latiano, T. P.; Cordio, S.; Passardi, A.; Tamburini, E.; Boni, L.; Falcone, A.; Cremolini, C. |